NO20043829L - Fremgangsmate for desolvatisering av solvater av atorvastatin-hemikalsium og atorvastatin-hemikalsium som i det vesentlige er fritt for organisk losemiddel - Google Patents
Fremgangsmate for desolvatisering av solvater av atorvastatin-hemikalsium og atorvastatin-hemikalsium som i det vesentlige er fritt for organisk losemiddelInfo
- Publication number
- NO20043829L NO20043829L NO20043829A NO20043829A NO20043829L NO 20043829 L NO20043829 L NO 20043829L NO 20043829 A NO20043829 A NO 20043829A NO 20043829 A NO20043829 A NO 20043829A NO 20043829 L NO20043829 L NO 20043829L
- Authority
- NO
- Norway
- Prior art keywords
- hemicalsium
- atorvastatin
- organic solvent
- essentially free
- desolvating
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title 2
- 229960005370 atorvastatin Drugs 0.000 title 2
- 239000003960 organic solvent Substances 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/04—Calcium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35849702P | 2002-02-19 | 2002-02-19 | |
| PCT/US2003/005216 WO2003070665A2 (en) | 2002-02-19 | 2003-02-19 | Desolvating solvates of atorvastatin hemi-calcium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20043829L true NO20043829L (no) | 2004-09-13 |
Family
ID=27757749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043829A NO20043829L (no) | 2002-02-19 | 2004-09-13 | Fremgangsmate for desolvatisering av solvater av atorvastatin-hemikalsium og atorvastatin-hemikalsium som i det vesentlige er fritt for organisk losemiddel |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US7122681B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1465901A4 (cg-RX-API-DMAC7.html) |
| JP (4) | JP4422488B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR20090045419A (cg-RX-API-DMAC7.html) |
| CN (1) | CN100379723C (cg-RX-API-DMAC7.html) |
| AU (1) | AU2003213171A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2475123A1 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20040767A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL163594A0 (cg-RX-API-DMAC7.html) |
| IS (1) | IS7407A (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04007995A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20043829L (cg-RX-API-DMAC7.html) |
| PL (1) | PL372241A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003070665A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200406229B (cg-RX-API-DMAC7.html) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US20040253305A1 (en) * | 2003-06-12 | 2004-12-16 | Luner Paul E. | Pharmaceutical compositions of atorvastatin |
| CN1997651B (zh) * | 2004-07-16 | 2012-06-06 | 力奇制药公司 | 阿托伐他汀钙的氧化降解产物 |
| CN101027282A (zh) * | 2004-07-22 | 2007-08-29 | 特瓦制药工业有限公司 | 阿托伐他汀半钙的新晶形及其制备方法 |
| MX2007002248A (es) * | 2004-08-25 | 2008-10-02 | Pfizer | Triazolobenzodiazepinas y su uso como antagonistas de vasopresina. |
| US20080009540A1 (en) * | 2004-09-30 | 2008-01-10 | Srinivasulu Gudipati | Amorphous Atorvastatin Calcium |
| EP1868993B1 (en) * | 2005-04-08 | 2014-04-30 | EGIS Gyógyszergyár Nyilvánosan Müködõ Részvénytársaság | Process for the preparation of a new crystalline atorvastatin hemicalcium salt polymorph form |
| KR20080007561A (ko) * | 2005-12-13 | 2008-01-22 | 테바 파마슈티컬 인더스트리즈 리미티드 | 아토바스타틴 헤미칼슘의 결정형 및 이의 제조 방법 |
| US20070265456A1 (en) * | 2006-05-09 | 2007-11-15 | Judith Aronhime | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IT1390848B1 (it) * | 2008-07-31 | 2011-10-19 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
| KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
| CN107108601B (zh) | 2014-08-28 | 2021-08-20 | 阿森纽荣股份公司 | 糖苷酶抑制剂 |
| US11261183B2 (en) * | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| WO2017144637A1 (en) | 2016-02-25 | 2017-08-31 | Asceneuron S. A. | Acid addition salts of piperazine derivatives |
| US10927105B1 (en) | 2017-05-23 | 2021-02-23 | Lundbeck La Jolla Research Center, Inc. | Pyrazole MAGL inhibitors |
| JOP20190267A1 (ar) * | 2017-05-23 | 2019-11-18 | Lundbeck La Jolla Research Center Inc | مثبطات بيرازول magl |
| JOP20190262B1 (ar) | 2017-05-23 | 2023-09-17 | H Lundbeck As | مثبطات بيرازول magl |
| ES2954474T3 (es) | 2018-08-22 | 2023-11-22 | Asceneuron Sa | Sales de adición de ácido de succinato y fumarato de derivados de piperazina útiles como inhibidores de glucosidasa |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US444129A (en) * | 1891-01-06 | Henry l | ||
| US4444129A (en) | 1982-11-05 | 1984-04-24 | Lecorp | Method of drying fine coal particles |
| DE3306250A1 (de) * | 1983-02-23 | 1984-08-23 | Basf Ag, 6700 Ludwigshafen | Sphaerische einkristalle fuer pharmazeutische zwecke |
| JPS59167676A (ja) | 1983-03-11 | 1984-09-21 | 株式会社 大川原製作所 | 多室型流動層乾燥機 |
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| GB8914804D0 (en) * | 1989-06-28 | 1989-08-16 | Glaxo Group Ltd | Process |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| CN1087288C (zh) * | 1995-07-17 | 2002-07-10 | 沃尼尔·朗伯公司 | 结晶[R－(R*,R*)]－2－(4－氟苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[(苯氨基)羰基]－1H－吡咯－1－庚酸半钙盐 |
| US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| TW385306B (en) | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
| EP1535613B1 (en) | 1999-11-17 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Process for preparing a polymorphic form of atorvastatin calcium |
| ATE309985T1 (de) | 1999-12-17 | 2005-12-15 | Pfizer Science & Tech Ltd | Herstellungsverfahren auf industrieller basis von atorvastatin trihydrat hemi-kalziumsalz in kristalliner form |
| AU780247B2 (en) | 1999-12-17 | 2005-03-10 | Pfizer Science And Technology Ireland Limited | A process for producing crystalline atorvastatin calcium |
| IL155734A0 (en) * | 2000-11-03 | 2003-11-23 | Teve Pharmaceutical Ind Ltd | Atorvastatin hemi-calcium form vii |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| ES2319870T3 (es) | 2000-12-27 | 2009-05-14 | Teva Pharmaceutical Industries Limited | Formas cristalinas de atorvastatina. |
| SI20814A (sl) | 2001-01-23 | 2002-08-31 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Priprava amorfnega atorvastatina |
| IN190564B (cg-RX-API-DMAC7.html) | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
| EE200300597A (et) * | 2001-06-29 | 2004-02-16 | Warner-Lambert Company Llc | [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[fenüülamino)karbonüül]-1H-pürrool-1-hepta anhappe kaltsiumsoola (2:1) (atorvastatiini) kristallilised vormid |
| CZ2004126A3 (cs) | 2001-07-30 | 2004-12-15 | Dr. Reddy's Laboratories Limited | Krystalické formy VI. A VII. vápenaté soli atorvastatinu |
| WO2003018547A2 (en) | 2001-08-31 | 2003-03-06 | Morepen Laboratories Ltd. | An improved process for the preparation of amorphous atorvastatin calcium salt (2:1) |
| CA2475864A1 (en) | 2002-02-15 | 2003-08-28 | Teva Pharmaceutical Industries Ltd. | Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation, as well as novel processes for preparing atorvastatin hemi-calcium forms i, viii and ix |
-
2003
- 2003-02-19 US US10/370,424 patent/US7122681B2/en not_active Expired - Fee Related
- 2003-02-19 KR KR1020097007464A patent/KR20090045419A/ko not_active Ceased
- 2003-02-19 CA CA002475123A patent/CA2475123A1/en not_active Abandoned
- 2003-02-19 AU AU2003213171A patent/AU2003213171A1/en not_active Abandoned
- 2003-02-19 KR KR1020097007465A patent/KR20090045420A/ko not_active Ceased
- 2003-02-19 JP JP2003569575A patent/JP4422488B2/ja not_active Expired - Fee Related
- 2003-02-19 HR HRP20040767 patent/HRP20040767A2/hr not_active Application Discontinuation
- 2003-02-19 PL PL03372241A patent/PL372241A1/xx unknown
- 2003-02-19 MX MXPA04007995A patent/MXPA04007995A/es active IP Right Grant
- 2003-02-19 EP EP03709217A patent/EP1465901A4/en not_active Withdrawn
- 2003-02-19 CN CNB038040913A patent/CN100379723C/zh not_active Expired - Fee Related
- 2003-02-19 KR KR10-2004-7012804A patent/KR20040086397A/ko not_active Ceased
- 2003-02-19 IL IL16359403A patent/IL163594A0/xx unknown
- 2003-02-19 WO PCT/US2003/005216 patent/WO2003070665A2/en not_active Ceased
-
2004
- 2004-08-04 ZA ZA200406229A patent/ZA200406229B/en unknown
- 2004-08-17 IS IS7407A patent/IS7407A/is unknown
- 2004-09-13 NO NO20043829A patent/NO20043829L/no not_active Application Discontinuation
-
2006
- 2006-10-02 US US11/542,339 patent/US20070027328A1/en not_active Abandoned
-
2009
- 2009-02-26 JP JP2009044173A patent/JP2009143957A/ja active Pending
- 2009-07-17 JP JP2009169170A patent/JP2009235100A/ja active Pending
-
2013
- 2013-03-13 JP JP2013050939A patent/JP2013136630A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005523285A (ja) | 2005-08-04 |
| CN100379723C (zh) | 2008-04-09 |
| US7122681B2 (en) | 2006-10-17 |
| US20070027328A1 (en) | 2007-02-01 |
| IS7407A (is) | 2004-08-17 |
| CN1633439A (zh) | 2005-06-29 |
| ZA200406229B (en) | 2006-06-28 |
| JP2009235100A (ja) | 2009-10-15 |
| EP1465901A4 (en) | 2006-02-01 |
| JP2013136630A (ja) | 2013-07-11 |
| KR20090045419A (ko) | 2009-05-07 |
| KR20040086397A (ko) | 2004-10-08 |
| WO2003070665A2 (en) | 2003-08-28 |
| WO2003070665A3 (en) | 2004-02-12 |
| MXPA04007995A (es) | 2004-11-26 |
| HRP20040767A2 (en) | 2004-12-31 |
| PL372241A1 (en) | 2005-07-11 |
| IL163594A0 (en) | 2005-12-18 |
| JP2009143957A (ja) | 2009-07-02 |
| CA2475123A1 (en) | 2003-08-28 |
| US20030216584A1 (en) | 2003-11-20 |
| EP1465901A2 (en) | 2004-10-13 |
| KR20090045420A (ko) | 2009-05-07 |
| AU2003213171A1 (en) | 2003-09-09 |
| JP4422488B2 (ja) | 2010-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20043829L (no) | Fremgangsmate for desolvatisering av solvater av atorvastatin-hemikalsium og atorvastatin-hemikalsium som i det vesentlige er fritt for organisk losemiddel | |
| NO20033560D0 (no) | Fremgangsmåte for spektral balansering av forskjövne seismiske data | |
| ATE375336T1 (de) | Triazolderivate als inhibitoren von11-beta- hydroxysteroid-dehydrogenase-1 | |
| ATE398105T1 (de) | Carbonylamino- derivativate als neue inhibitoren von histone deacetylase | |
| DE60321808D1 (de) | Flavon derivate als inhibitoren von cyclin-abhängigen kinasen | |
| NO20043158L (no) | Substituerte kinazolinderivater som inhibitorer av aurorakinaser | |
| DE60221875D1 (de) | 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren | |
| NO20024921D0 (no) | Kombinasjon av organiske forbindelser | |
| NO20024920D0 (no) | Kombinasjon av organiske forbindelser | |
| DK1657246T3 (da) | Fremgangsmåde til forbedring af renhed og udbytte af sucralose | |
| NO20044194L (no) | Nye inhibitorer av histon-deacetylase | |
| NO20045220L (no) | Heterocykliske inhibitorer for kinaser | |
| DE60234167D1 (de) | Bipiperidin-derivate und ihre verwendung als inhibitoren der chemokinrezeptoren | |
| NO20015274D0 (no) | ACE-2 inhiberende forbindelser og fremgangsmåter for anvendelse derav | |
| DE60332036D1 (de) | Einteilige hand-airbrush | |
| EA200300925A1 (ru) | Новый способ промышленного синтеза ранелата стронция и его гидратов | |
| NO20042679L (no) | Inhibitorer av cytosolisk fosfolipase A2 | |
| EP1539248A4 (en) | INHIBITOR OF S100-p53 PROTEIN-PROTEIN INTERACTION AND METHOD OF SUPPRESSING CANCER USING THIS HEMMER | |
| NO20044016L (no) | Fremgangsmate for nedad-ekstrapolering av seismiske data | |
| AU2003207342A1 (en) | Cleaning device for cleaning of metal strings of musical instruments | |
| AU2003281220A1 (en) | N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/ or serotonin reuptake inhibitors | |
| NO20033488L (no) | Prövetaking av hydrokarboner fra geologiske formasjoner | |
| ITMI20031451A1 (it) | Derivati diidro-ftalazinici inibitori della fosfodiesterasi 4 | |
| NO20034124L (no) | Sammensetning av et taxan og en cyclinavhengig kinaseinhibitor | |
| PT1231206E (pt) | Composicoes estabilizadas de peroxidicarbonatos organicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |